Neuway Pharma appoints advisory board member

Biotech start-up company NEUWAY Pharma has appointed Dr. Wolfgang Baiker as a new Member of its advisory board. NEUWAY Pharma GmbH was founded in April 2014 as the first spin-off from Life Science Inkubator, Bonn, and secured series A financing from a syndicate led by Wellington Partners.

Nosto Solutions picks up $5.5 mln

Finnish e-commerce software firm Nosto Solutions said Tuesday that it has closed $5.5 million in funding. Wellington Partners led the round with participation from Open Ocean Capital, SanomaVentures and Tekes, the Finnish Funding Agency for Innovation.

Definiens gets further backing

Wellington Partners and Gilde Healthcare have co-led an investment round in Munich, Germany-based Definiens. Existing investors Cipio Partners and TVM Capital also participated.


Wellington Partners leads NEUWAY Series A

Wellington Partners has led a series A financing round at German-based NEUWAY Pharma GmbH. The business is the first spin-off from Life Science Inkubator in Bonn. NEUWAY is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases.


Gamma Capital, Texas Atlantic and Wellington Partners back Opvizor

Opvizor has received an undisclosed amount of funding. The investors were Gamma Capital Partners, Texas Atlantic Capital and Wellington Partners. In conjunction with the funding, Moshe Bar, general partner of Texas Atlantic Capital, has been named to Opvizor’s board of directors. Based in Houston, Opvizor is a provider of predictive analysis and issue prevention in virtual datacenter environments.

Invendo Medical scores $28 mln

Invendo Medical said Thursday that it has raised $28 million in financing. Xeraya Capital led the round with participation from other investors that included TVM Capital, Wellington Partners and 360° Capital. Based in New York and Kissing, Germany, Invendo Medical is a colonoscopy system maker.

Glo AB completes $30 mln Series D

Glo has completed a $30 million Series D financing. Glo provides high-quality light source solutions for displays, illumination, and automotive sectors. A new investor led the round, with participation from existing shareholders including Wellington Partners, Teknoinvest, Nano Future Invest, Energy Future Invest, Foundation Asset Management and others.

Daniel Waterhouse joins Balderton Capital

Balderton Capital has appointed Daniel Waterhouse, formerly at Wellington Partners, as a general partner. Waterhouse will be based in London and will help lead early stage investments in the software and internet sectors.

immatics biotechnologies closes Series D

immatics biotechnologies has closed a Series D financing round. The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer.

Middle Peak Raises $8.5M From Wellington, Seventure, Grunderfonds

Middle Peak Medical said it raised $8.5 million in a Series A financing in a deal co-led by Wellington Partners and Seventure Partners, along with seed investor High-Tech Gründerfonds Management GmbH. The money will fund development of Middle Peak’s technology for treating mitral valve disease

Gentical Raises $23.7M From Wellington, EdRIP, InnoBio, Others

Wellington Partners said it is the lead investor in a $23.7 million Series C financing round for Genticel which was closed this week. Wellington Partners committed about $5 million and the remaining came from existing shareholders, including EdRIP, IDInvest, InnoBio, IRDI and Amundi. The funds will be used primarily to finance a phase II program for the Toulouse, France-based HPV- vaccine developer’s lead product ProCervix.

Genticel Inks Over $20m Led by Wellington

Genticel, a biopharmaceutical company developing innovative vaccines for patients infected with human papillomavirus (HPV), has raised 18.2 million euros ($23.7 million) in additional capital. Wellington Partners led the round which included all current institutional investors IDInvest Partners, Edmond de Rothschild Investment Partners (EdRIP), InnoBio fund*, IRDI and Amundi Private Equity Funds.

Wellington Leads Genticel Financing

Wellington Partners has led a 18.2 million euros series C financing round at Toulouse/France-based therapeutic HPV- vaccine developer Genticel. Wellington Partners committed 4 million euros to this financing. The remaining 14.2 million euros were provided by the existing shareholders including EdRIP, IDInvest, InnoBio, IRDI and Amundi.

Wellington Partners Life Science Team Hires Venture Partner

Wellington Partners has appointed Stuart M. Essig as a new venture partner for the life science investment team. Essig currently serves as chairman of the board of directors of Integra Life Sciences, a NASDAQ-listed company he built during his tenure as CEO to more than $800 million in revenues and $1.6 billion in enterprise value.

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget